Mode
Text Size
Log in / Sign up
N/A Completed N=8,040

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

Source: ClinicalTrials.gov NCT00676520 ↗
Enrolled (actual)
8,040
Serious AEs
33.4%
Results posted
Nov 2012
Primary outcomePrimary: Stent Thrombosis (Definite and Probable) Rate as Defined by ARC (Academic Research Constortium). — 0.81 percentage of participants

Summary

XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

Outcome Measures

OutcomeResultp-value
PRIMARY
Stent Thrombosis (Definite and Probable) Rate as Defined by ARC (Academic Research Constortium).
0.81 —
PRIMARY
Composite Rate of Cardiac Death and Any Myocardial Infarction (MI)
7.2 —
SECONDARY
Clinical Device Success
99.8 —
SECONDARY
Procedural Success
97.3 —
SECONDARY
Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)
5.4 —
SECONDARY
Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)
8.3 —
SECONDARY
Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])
14.9 —
SECONDARY
Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)
9.6 —
SECONDARY
Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)
2.6 —
SECONDARY
Any MI (Q-wave and Non Q-wave)
6.3 —
SECONDARY
Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)
9.2 —
SECONDARY
Major Bleeding Complications
2.8 —
SECONDARY
Dual Antiplatelet Medication Usage
79.9 —
SECONDARY
Dual Antiplatelet Therapy Non-compliance Through 1 Year
18.0 —
SECONDARY
Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)
9.4 —
SECONDARY
Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)
76.0 —
SECONDARY
SAQ (Seattle Angina Questionaire)
76.0; 54.3; 90.7; 92.2; 78.0 —

Eligibility Criteria

Inclusion Criteria

  • The patient agrees to participate in this study by signing the Institutional Review Board approved informed consent form.

Exclusion Criteria

  • The inability to obtain an informed consent.

Age limit is determined by investigator.

There are no angiographic inclusion or exclusion criteria for this study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00676520). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search